Page results
-
This information provides information for women who have chosen to have surgical management using local anaesthetic following their diagnosis of a miscarriage.
-
Information about total penectomy and perineal urethrostomy for patients referred to UCLH.
-
Information about the council of governors at University College London Hospitals NHS Foundation Trust
-
This page explains what a cervical cerclage involves and the risks and benefits of the procedure.
-
This page provides information about the support you can have with some of your concerns while living with myeloma.
-
This page provides information on the purpose of diet in helping to manage the symptoms of Crohn’s disease in the remission phase.
-
The pelvic pain management service at UCLH was established in 2006 and our clinicians have a wealth of experience in managing women with abdominal and pelvic pain, and especially with those who have experienced complications following mesh implantation.
-
Her Majesty The Queen’s state funeral will be held on Monday 19 September, and will be a national bank holiday.
-
Patient information for women who have chosen to have surgical management under general anaesthetic following a diagnosis of a miscarriage.
-
In partnership with Camden MSK, our department has agreed to provide ultrasound-guided Caudal Epidural injections to patients referred by the Camden community MSK services.
File results
-
FOI/2024/0360 - Radiology Information System (RIS) supplier/ contract/ staff details
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0513 - Robotic platforms for surgery costs/ contract
-
FOI/2024/0514 - Viscosupplementation injections/ spend
-
FOI/2024/0518 - Post partum balloons buying/ usage numbers
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer